OTCMKTS:ALPMY - Astellas Pharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$15.32
▼ -0.24 (-1.54%)

This chart shows the closing price for ALPMY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Astellas Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALPMY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALPMY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Astellas Pharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a -100.00% upside from the last price of $15.32.

This chart shows the closing price for ALPMY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Astellas Pharma. This rating has held steady since April 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/10/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/10/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/9/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/7/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/5/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/4/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/12/2022CitigroupInitiated CoverageBuy
2/23/2022Jefferies Financial GroupDowngradeBuy ➝ Hold
6/29/2021Jefferies Financial GroupDowngradeBuy ➝ Hold
5/26/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy
1/23/2020Morgan StanleyInitiated CoverageOverweight
9/24/2019Jefferies Financial GroupInitiated CoverageBuy
11/5/2018JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
9/13/2018Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
6/8/2018The Goldman Sachs GroupDowngradeBuy ➝ Neutral
(Data available from 7/5/2017 forward)

News Sentiment Rating

0.70 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/6/2021
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/5/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/4/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
3/6/2022
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/5/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/5/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
6/4/2022
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/4/2022

Current Sentiment

  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Astellas Pharma logo
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.
Read More

Today's Range

Now: $15.32
Low: $14.77
High: $15.32

50 Day Range

MA: $15.38
Low: $14.54
High: $16.21

52 Week Range

Now: $15.32
Low: $14.21
High: $18.18

Volume

42,400 shs

Average Volume

104,754 shs

Market Capitalization

$28.13 billion

P/E Ratio

25.53

Dividend Yield

1.76%

Beta

0.55

Frequently Asked Questions

What sell-side analysts currently cover shares of Astellas Pharma?

The following sell-side analysts have issued stock ratings on Astellas Pharma in the last twelve months: Citigroup Inc., and Jefferies Financial Group Inc..
View the latest analyst ratings for ALPMY.

What is the current price target for Astellas Pharma?

0 Wall Street analysts have set twelve-month price targets for Astellas Pharma in the last year.
View the latest price targets for ALPMY.

What is the current consensus analyst rating for Astellas Pharma?

Astellas Pharma currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ALPMY will outperform the market and that investors should add to their positions of Astellas Pharma.
View the latest ratings for ALPMY.

How do I contact Astellas Pharma's investor relations team?

Astellas Pharma's physical mailing address is 2-5-1 Nihonbashi-Honcho Chuo-Ku, Tokyo M0, 103-8411. The company's listed phone number is (133) 244-3000. The official website for Astellas Pharma is www.astellas.com. Learn More about contacing Astellas Pharma investor relations.